CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · Real-Time Price · USD
2.110
-0.170 (-7.46%)
Sep 8, 2025, 10:51 AM - Market open
CytomX Therapeutics Employees
As of December 31, 2024, CytomX Therapeutics had 121 total employees, including 119 full-time and 2 part-time employees. The number of employees decreased by 1 or -0.82% compared to the previous year.
Employees
121
Change (1Y)
-1
Growth (1Y)
-0.82%
Revenue / Employee
$1,166,116
Profits / Employee
$396,554
Market Cap
347.97M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 121 | -1 | -0.82% |
Dec 31, 2023 | 122 | 4 | 3.39% |
Dec 31, 2022 | 118 | -60 | -33.71% |
Dec 31, 2021 | 178 | 32 | 21.92% |
Dec 31, 2020 | 146 | -14 | -8.75% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
CTMX News
- 11 days ago - CytomX Therapeutics to Present at Upcoming September Investor Conferences - GlobeNewsWire
- 26 days ago - CytomX Therapeutics Provides Update on CX-2051 Phase 1 Study - GlobeNewsWire
- 4 weeks ago - CytomX Therapeutics, Inc. (CTMX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - CytomX Therapeutics: Updated Outlook For Late 2025 - Seeking Alpha
- 4 weeks ago - CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 5 weeks ago - CytomX Therapeutics to Report Second Quarter 2025 Financial Results on August 7, 2025 - GlobeNewsWire
- 3 months ago - CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference - GlobeNewsWire
- 4 months ago - CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Melanoma - GlobeNewsWire